Implementation of CT-P13 via a Managed Switch Programme in Crohn's Disease: 12-Month Real-World Outcomes

Nikolas Plevris; Gareth R Jones; Philip W Jenkinson; Mathew Lyons; Cher S Chuah; Lynne M Merchant; Rebecca J Pattenden; Eleanor F Watson; Gwo-Tzer Ho; Colin L Noble; Shahida Din; Alan G Shand; Ian D Arnott; Charlie W Lees

doi:10.1007/s10620-018-5406-8

Implementation of CT-P13 via a Managed Switch Programme in Crohn's Disease: 12-Month Real-World Outcomes

Nikolas Plevris, Gareth R Jones, Philip W Jenkinson, Mathew Lyons, Cher S Chuah, Lynne M Merchant, Rebecca J Pattenden, Eleanor F Watson, Gwo-Tzer Ho, Colin L Noble, Shahida Din, Alan G Shand, Ian D Arnott, Charlie W Lees

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND: Switching from Remicade to CT-P13 allows for significant cost savings and has been shown to be non-inferior to continued therapy with Remicade for the treatment of Crohn's disease.

AIM: The aim of this work was to prospectively evaluate clinical outcomes in a cohort of patients with Crohn's disease switching from Remicade to CT-P13.

METHODS: A prospective service evaluation was performed. The Harvey-Bradshaw index, CRP, faecal calprotectin and serum for infliximab/antibody levels were collected prior to patients' final Remicade infusion and at 6 and 12 months after switching to CT-P13 as part of routine clinical care. All adverse events during follow-up were also recorded.

RESULTS: One hundred and ten patients on Remicade switched to CT-P13. No significant difference was observed between the Harvey-Bradshaw Index (p = 0.07), CRP (p = 0.13), faecal calprotectin (p = 0.25) or trough infliximab levels (p = 0.47) comparing before and at 6 and 12 months after the switch to CT-P13. Seven patients developed new infliximab antibodies after switching from Remicade to CT-P13. The majority of patients remained on CT-P13 at 12 months (84.5%) and the rate of adverse events and serious adverse events was 53.8 and 13.5 per 100 patient-years of follow-up, respectively. Switching to CT-P13 resulted in a cost saving of approximately 46.4%.

CONCLUSION: The transition to CT-P13 from Remicade for the treatment of Crohn's disease is safe and has no negative effect on clinical outcomes at 12 months.

Original language	English
Journal	Digestive Diseases and Sciences
Early online date	7 Dec 2018
DOIs	https://doi.org/10.1007/s10620-018-5406-8
Publication status	E-pub ahead of print - 7 Dec 2018

Access to Document

10.1007/s10620-018-5406-8

Cite this

Plevris, N., Jones, G. R., Jenkinson, P. W., Lyons, M., Chuah, C. S., Merchant, L. M., Pattenden, R. J., Watson, E. F., Ho, G.-T., Noble, C. L., Din, S., Shand, A. G., Arnott, I. D., & Lees, C. W. (2018). Implementation of CT-P13 via a Managed Switch Programme in Crohn's Disease: 12-Month Real-World Outcomes. Digestive Diseases and Sciences. Advance online publication. https://doi.org/10.1007/s10620-018-5406-8

@article{acbc9463bd79409f9aa704856257f658,

title = "Implementation of CT-P13 via a Managed Switch Programme in Crohn's Disease: 12-Month Real-World Outcomes",

abstract = "BACKGROUND: Switching from Remicade to CT-P13 allows for significant cost savings and has been shown to be non-inferior to continued therapy with Remicade for the treatment of Crohn's disease.AIM: The aim of this work was to prospectively evaluate clinical outcomes in a cohort of patients with Crohn's disease switching from Remicade to CT-P13.METHODS: A prospective service evaluation was performed. The Harvey-Bradshaw index, CRP, faecal calprotectin and serum for infliximab/antibody levels were collected prior to patients' final Remicade infusion and at 6 and 12 months after switching to CT-P13 as part of routine clinical care. All adverse events during follow-up were also recorded.RESULTS: One hundred and ten patients on Remicade switched to CT-P13. No significant difference was observed between the Harvey-Bradshaw Index (p = 0.07), CRP (p = 0.13), faecal calprotectin (p = 0.25) or trough infliximab levels (p = 0.47) comparing before and at 6 and 12 months after the switch to CT-P13. Seven patients developed new infliximab antibodies after switching from Remicade to CT-P13. The majority of patients remained on CT-P13 at 12 months (84.5%) and the rate of adverse events and serious adverse events was 53.8 and 13.5 per 100 patient-years of follow-up, respectively. Switching to CT-P13 resulted in a cost saving of approximately 46.4%.CONCLUSION: The transition to CT-P13 from Remicade for the treatment of Crohn's disease is safe and has no negative effect on clinical outcomes at 12 months.",

author = "Nikolas Plevris and Jones, {Gareth R} and Jenkinson, {Philip W} and Mathew Lyons and Chuah, {Cher S} and Merchant, {Lynne M} and Pattenden, {Rebecca J} and Watson, {Eleanor F} and Gwo-Tzer Ho and Noble, {Colin L} and Shahida Din and Shand, {Alan G} and Arnott, {Ian D} and Lees, {Charlie W}",

year = "2018",

month = dec,

day = "7",

doi = "10.1007/s10620-018-5406-8",

language = "English",

journal = "Digestive Diseases and Sciences",

issn = "0163-2116",

publisher = "Springer",

}

TY - JOUR

T1 - Implementation of CT-P13 via a Managed Switch Programme in Crohn's Disease

T2 - 12-Month Real-World Outcomes

AU - Plevris, Nikolas

AU - Jones, Gareth R

AU - Jenkinson, Philip W

AU - Lyons, Mathew

AU - Chuah, Cher S

AU - Merchant, Lynne M

AU - Pattenden, Rebecca J

AU - Watson, Eleanor F

AU - Ho, Gwo-Tzer

AU - Noble, Colin L

AU - Din, Shahida

AU - Shand, Alan G

AU - Arnott, Ian D

AU - Lees, Charlie W

PY - 2018/12/7

Y1 - 2018/12/7

N2 - BACKGROUND: Switching from Remicade to CT-P13 allows for significant cost savings and has been shown to be non-inferior to continued therapy with Remicade for the treatment of Crohn's disease.AIM: The aim of this work was to prospectively evaluate clinical outcomes in a cohort of patients with Crohn's disease switching from Remicade to CT-P13.METHODS: A prospective service evaluation was performed. The Harvey-Bradshaw index, CRP, faecal calprotectin and serum for infliximab/antibody levels were collected prior to patients' final Remicade infusion and at 6 and 12 months after switching to CT-P13 as part of routine clinical care. All adverse events during follow-up were also recorded.RESULTS: One hundred and ten patients on Remicade switched to CT-P13. No significant difference was observed between the Harvey-Bradshaw Index (p = 0.07), CRP (p = 0.13), faecal calprotectin (p = 0.25) or trough infliximab levels (p = 0.47) comparing before and at 6 and 12 months after the switch to CT-P13. Seven patients developed new infliximab antibodies after switching from Remicade to CT-P13. The majority of patients remained on CT-P13 at 12 months (84.5%) and the rate of adverse events and serious adverse events was 53.8 and 13.5 per 100 patient-years of follow-up, respectively. Switching to CT-P13 resulted in a cost saving of approximately 46.4%.CONCLUSION: The transition to CT-P13 from Remicade for the treatment of Crohn's disease is safe and has no negative effect on clinical outcomes at 12 months.

AB - BACKGROUND: Switching from Remicade to CT-P13 allows for significant cost savings and has been shown to be non-inferior to continued therapy with Remicade for the treatment of Crohn's disease.AIM: The aim of this work was to prospectively evaluate clinical outcomes in a cohort of patients with Crohn's disease switching from Remicade to CT-P13.METHODS: A prospective service evaluation was performed. The Harvey-Bradshaw index, CRP, faecal calprotectin and serum for infliximab/antibody levels were collected prior to patients' final Remicade infusion and at 6 and 12 months after switching to CT-P13 as part of routine clinical care. All adverse events during follow-up were also recorded.RESULTS: One hundred and ten patients on Remicade switched to CT-P13. No significant difference was observed between the Harvey-Bradshaw Index (p = 0.07), CRP (p = 0.13), faecal calprotectin (p = 0.25) or trough infliximab levels (p = 0.47) comparing before and at 6 and 12 months after the switch to CT-P13. Seven patients developed new infliximab antibodies after switching from Remicade to CT-P13. The majority of patients remained on CT-P13 at 12 months (84.5%) and the rate of adverse events and serious adverse events was 53.8 and 13.5 per 100 patient-years of follow-up, respectively. Switching to CT-P13 resulted in a cost saving of approximately 46.4%.CONCLUSION: The transition to CT-P13 from Remicade for the treatment of Crohn's disease is safe and has no negative effect on clinical outcomes at 12 months.

U2 - 10.1007/s10620-018-5406-8

DO - 10.1007/s10620-018-5406-8

M3 - Article

C2 - 30535885

SN - 0163-2116

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

ER -

Implementation of CT-P13 via a Managed Switch Programme in Crohn's Disease: 12-Month Real-World Outcomes

Abstract

Access to Document

Fingerprint

Cite this